Warnings and Precautions: Gallbladder abnormalities may occur: Patients should be monitored periodically. Glucose Metabolism: Hypoglycemia or hyperglycemia may occur. Blood glucose levels should…
Novartis Oncology shares your commitment to helping patients receive the medicines prescribed. Patient Assistance Now Oncology (PANO) provides access to information and our wide range of resources available to your patients in over 160 languages.
Support for patients includes:
To learn more, call 1-800-282-7630.
At Novartis Oncology, we’ve made it easier than ever for patients to access financial support on their prescription costs for almost all Novartis Oncology products.
With the Novartis Oncology Universal Co-Pay Program, eligible, commercially insured patients may pay no more than $25 per month, and Novartis will pay the remaining co-pay, up to $15,000 per calendar year.
Limitations apply. Offer is not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice.
Encourage your patients to find out if they are eligible to enroll in the Universal Co-Pay Program by visiting www.CoPay.NovartisOncology.com or calling 1-877-577-7756.
When caring for patients who are receiving Sandostatin® LAR Depot (octreotide acetate for injectable suspension) therapy, you know how important it is to administer injections exactly as prescribed. But you also know that it's not always easy for some of your patients to get to the office to receive their injections by a trained health care provider.
The Sandostatin Mobile Administration Program is not intended to replace the care provided by you and your office, but to help eligible patients receive their injections on schedule at home or at a location convenient to them, by a trained health care professional. Through this program, you will receive regular patient reports, to keep you up to date on your patients' receipt of Sandostatin LAR Depot injections.
Which patients are eligible?
The MAP is an additional benefit for all appropriate and eligible patients with acromegaly for whom Sandostatin LAR Depot has been prescribed.
Your office can confirm patient eligibility easily by calling 1-877-503-3377 and speaking with a representative. You can also print the enrollment form by clicking here.
Advantages of the MAP
Because the program provides specially trained registered nurses, you can feel confident about the following:
How MAP works
Important things to note about the MAP
SANDOSTATIN® LAR Depot
Sandostatin LAR Depot (octreotide acetate for injectable suspension) is indicated for patients in whom initial treatment with immediate release Sandostatin (octreotide acetate) Injection has been shown to be effective and tolerated for long-term maintenance therapy in acromegalic patients who have had inadequate response to surgery and/or radiotherapy or for whom surgery and/or radiotherapy is not an option (the goal of treatment in acromegaly is to reduce GH and IGF-1 levels to normal).
IMPORTANT SAFETY INFORMATION
Warnings and Precautions:
The following drugs require monitoring and possible dose adjustment when used with Sandostatin LAR Depot: cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine. Octreotide has been associated with alterations in nutrient absorption, so it may have an effect on absorption of orally administered drugs. Drugs mainly metabolized by CYP3A4 and which have a low therapeutic index should be used with caution.
The most common adverse reactions occurring in patients receiving Sandostatin LAR Depot were biliary abnormalities (52%), diarrhea (36–48%), cholelithiasis (13–38%), abdominal pain or discomfort (11–29%), flatulence (26%), influenza-like symptoms (20%), constipation (19%), headache (15%), anemia (15%), hyperglycemia (15%), injection site pain (2–14%), hypertension (13%), dizziness (12%), fatigue (11%), nausea (10%), vomiting (7%), hypothyroidism (2%), hypoglycemia (2%), and goiter (2%).
Please see full Prescribing Information.